Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.71 USD | -2.71% | +5.94% | +217.24% |
Financials (USD)
Sales 2024 * | 14.77M | Sales 2025 * | 12.14M | Capitalization | 2.82B |
---|---|---|---|---|---|
Net income 2024 * | -292M | Net income 2025 * | -326M | EV / Sales 2024 * | 191 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 233 x |
P/E ratio 2024 * |
-8.93
x | P/E ratio 2025 * |
-8.43
x | Employees | 253 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.29% |
Latest transcript on Avidity Biosciences, Inc.
1 day | -2.71% | ||
1 week | +10.17% | ||
Current month | +18.98% | ||
1 month | +20.08% | ||
3 months | +112.20% | ||
6 months | +360.83% | ||
Current year | +217.24% |
Managers | Title | Age | Since |
---|---|---|---|
Troy Wilson
FOU | Founder | 55 | 12-11-12 |
Sarah Boyce
CEO | Chief Executive Officer | 52 | 19-09-30 |
Michael MacLean
DFI | Director of Finance/CFO | 58 | 20-05-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arthur Levin
BRD | Director/Board Member | 70 | 13-09-30 |
Carsten Boess
BRD | Director/Board Member | 57 | 20-04-12 |
Edward Kaye
BRD | Director/Board Member | 75 | 19-08-21 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.11% | 0 M€ | 0.00% | - | |
0.08% | 0 M€ | 0.00% | - | |
0.08% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 28.72 | -2.68% | 1,074,984 |
24-05-15 | 29.51 | +2.08% | 1,680,704 |
24-05-14 | 28.91 | +11.11% | 1,798,074 |
24-05-13 | 26.02 | +0.23% | 783,775 |
24-05-10 | 25.96 | -4.21% | 1,162,942 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+217.24% | 2.82B | |
+0.10% | 91.42B | |
+3.16% | 41.08B | |
-11.10% | 34.26B | |
+53.99% | 25.27B | |
-9.41% | 12.81B | |
-12.25% | 11.6B | |
-44.00% | 11.42B | |
+5.77% | 9.16B | |
-6.90% | 8.22B |
- Stock Market
- Equities
- RNA Stock